Safi Landskroner

Safi Landskroner has over two decades of experience in the medical industry. From 1998 to 2009, they held the role of VP Generic Business Development & Regulatory Affairs and Head of Regulatory Affairs at Dexcel Pharma. From 2009 to 2012, they were the Business Development- VP at Neopharm Group. From 2012 to 2018, they were the Procurement Division Manager at Meuhedet, responsible for medical procurement activities and budget (drugs and devices). In 2018, they moved to Chartwell Pharmaceuticals as VP Business Development. From 2013 to 2022, they were VP Business Development at Mapi Pharma. Currently, they are VP Business Development & Marketing at Epitomee Medical. Additionally, they have held the role of Director (Board Member) at Protea Vaccine Technologies Ltd from 2009 to 2012 and at NasVax Ltd. (TASE- NSVX, currently TASE: THXBY) from 2006 to 2009.

Safi Landskroner obtained a B.Pharm from The Hebrew University of Jerusalem between 1989 and 1993. Safi then attended Technion - Israel Institute of Technology, where they earned a Diploma in Marketing Management in 1994-1995. Safi went on to receive an Executive MBA from the University of Bradford between 1996 and 2000. In 2006, they completed the Merage Foundation Program in Marketing and Biz. Dev. Safi also attended The Hebrew Reali School.